Beta Drugs LtdQ3 FY22Pharmaceuticals & Biotechnology

Beta Drugs Ltd

Q3 FY22 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Beta Drugs expects to achieve around Rs. 230 crores revenue for the full year, with potential to surpass this after product conversions in January-February (Page 17).
→Company targets 25% to 30% growth annually over the next 3-4 years, driven primarily by oncology portfolio and export markets like LATAM, African, Asian, and CIS regions (Pages 11, 13).
→Exports, especially formulation exports, are major growth drivers; plans to file over 200 dossiers in 2-3 years and expand market presence in regulated and semi-regulated markets (Page 4).
→Cosmetic-Dermatology division aims for Rs. 30-35 crores topline in 3 years, with plans to build a strong brand and own manufacturing plant in 2-3 years (Pages 5, 16).
→CRAMs (contract manufacturing) business is steadily growing with 28-30 customers and addition of new clients expected, contributing progressively to revenues (Pages 16, 17).

Category 3

→Beta Drugs expects revenue growth of 25% to 30% over the next 3-4 years, driven primarily by oncology portfolio and export expansion into LATAM, African, Asian, and CIS markets.
→EBITDA margins for oncology currently exceed 30-35%, with derma/cosmetology segment target margins conservatively at 15-17%, expected to improve to oncology levels once own production commences in 2-3 years.
→Gross margins improved from 37% (H1 last year) to ~42% this year; material cost as percentage of sales reduced from 73% to 68%.
→Receivable days steady around 90-96 days, indicating stable cash cycle.
→Operating cash flow dipped in H1 FY23 due to CAPEX creditor payments but overall financials remain strong.
→CAPEX focus on injectable facility upgrades and new API line to support margin expansion and volume growth.
→Management confident in sustaining strong earnings growth and profitability aligned with revenue trajectory and margin expansion plans.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.

→There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
→The company discusses internal CAPEX investments, such as Rs. 8.8 crores spent in H1 FY23 mainly for capacity expansion and upgradation, without indicating external fundraising.
→Rahul Batra mentions no major CAPEX requirements for the next 2-3 years until turnover reaches Rs. 400-450 crores, suggesting reliance on internal accruals.
→The company is focusing on growth via expanding exports, CRAMs, and a new Cosmetics/Dermatology division without reference to raising external funds.
→No direct references to plans for debt or equity issuance were made during the call.

Yes

→Rahul Batra mentioned expecting a few conversions/orders in January and February which can help surpass the Rs. 230 crore revenue figure for the full year.
→The company currently has clear orders from some good clients in the CRAMs (contract manufacturing) division.
→Agreements for these clients are expected to be finalized by December, with commercial production starting by January or February.
→The CRAMs business has added 3 to 4 new customers this year and plans to add another 3 to 4 in the next year.
→No specific numeric value of the current order book or pending orders was disclosed, but the tone indicates a healthy pipeline with expected growth.

Yes

→Beta Drugs has invested around Rs. 4 to 5 crores in scaling up a new API production line, focusing on exports, especially regulated markets (Page 4).
→In April 2022, installed a large Lyophilizer increasing injectable capacity threefold; invested Rs. 1.5 crores on this and Rs. 2.5 crores on upgrading injectable facilities including HVAC system and filter validations (Page 13).
→Rs. 8.8 crores CAPEX incurred in H1 FY23 mainly on Lyophilizer and injectable facility upgrades (Page 13).
→New API production line machinery installation planned to commence by December 2022 (Page 4, 13).
→Land acquired for setting up a new plant for Dermatology and Cosmetology division, with plans to build own manufacturing plant in next 2-3 years (Pages 5, 6).
→No major CAPEX expected for next 2-3 years till turnover reaches Rs. 400-450 crores, leveraging existing capacities (Page 13).

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Beta Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.